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prolactin secretion by the pituitary. One of these compounds (ergocryptine) has been used in the treatment of breast cancer patients but with no result (EORTC Breast Cancer Group 1972a) . Some improvement has been reported in the overall response rate from adrenalectomy by the simultaneous use of 5-fluorouracil (Wilson et al. 1972 ). The combination of treatments seems to be of particular value in patients with a short free interval and with visceral disease.
Tests ofPrediction
Much work has been carried out during the past twenty-five years to produce a method of identifying those women who stand a good chance of responding to adrenalectomy or hypophysectomy, but few of the methods introduced have stood the test oftime. The longest standing method relies on an estimation of the amounts of androgen and cortisol metabolites in urine taken from patients before operation; high androgen and low corticosteroids being associated with a good response and vice versa. The degree of prediction given by this test is far from perfect but, taken in association with the free period and the menopausal status, it can identify patients vho stand a minimal chance of respondingand this can be of material help in managing these patients (Atkins et al. 1968 ).
More recently the measurement of cestrogen receptor sites in the tumour has become possible and preliminary work indicates that the estimations can be used to identify women who stand a good chance of responding to hormone administration or to ablative procedures (Jensen et al. 1971) . This test, possibly used together with an assessment of the endocrine environment, may facilitate much more accurate prediction.
Probably it is in this field of prediction that most developments will be made in the future. At present most hormone therapies for advanced breast cancer are given on an empirical basis. The decision on the efficacy of a treatment is made usually by trying it in practice. With the development of more sophisticated assays, both of endocrine status and of the tumour's potential response, accurate assessment should be possible. Eventually, indications for the various treatments currently in use should be recognized, and it will be possible to find out whether or not a tumour is responsive and to which hormone or combination of hormones it will react. Only then will a precise and optimal regime of treatment be able to be devised for each patient.
Dr Philip Peacock (Rustington, retired): Sir George
Beatson was a Manxman and we first met in Glasgow in 1928. Beatson's ideas emanated from the observation that lactation was prolonged in cattle after castration. The first patient with advanced mammary cancer on whom he carried out the operation of oophorectomy, in 1896, survived 4 years.
Dr Basil A Stoll (St Thomas's Hospital, London): Prolactin has been shown to increase the mitotic activity of experimental mammary cancer, and it was hoped that the separation of prolactin from human growth hormone would greatly increase knowledge of the mechanisms of hormonal therapy in breast cancer.
However, although prolactin has been isolated and assayed, no great advances have been achieved so far. Both 2-a-bromoergocryptine and levodopa, which reduce prolactin levels, should have a beneficial effect on breast cancer, but this has not been my experience. On the other hand, pituitary stalk section increases the level of prolactin enormously, yet in some patients milk has been expressed from one breast while the tumour in the other breast has regressed in size. Furthermore, we were surprised when a group of workers in Belgium showed that administration of cestrogens at high dosage in fact increased the level of prolactin rather than decreased it. The place of prolactin in breast cancer is still uncertain.
We should be able to use our existing methods of therapy much more effectively. (Estrogen-induced stimulation could possibly be converted into an cestrogen-induced regression if the variable dose relationships were known. Titration of hormones against tumour in tissue culture preparations to determine the most effective treatment in the patient does not seem to be particularly rewarding at present, but the technique may improve in the future.
Dr H W C Ward (Birmingham): Tamoxifen, an anticestrogen, has been used in Birmingham for the past two years and we have found a good response in soft tissue disease. The results in bone metastases were disappointing and worse than with androgen therapy. Sixty per cent of soft tissue tumours responded, by reduction in size, to 10 mg twice daily, whereas 77% responded to a dose of 20 mg twice daily; 40 mg twice daily had no extra advantage and produced worse side-effects of nausea and hot flushes. However, if a 50% reduction in tumour size was used to indicate response, then only 40 % of tumours did so respond.
